MKI67 and neoplasm: Furthermore, tumour cell growth of vemurafenib resistant SKMel28 R, which were seeded into an organotypic skin reconstruct, was markedly impaired by treatment with BI-D1870 in addition to vemurafenib for 10 days, as indicated by a lack of cells with positive staining for the proliferation marker Ki67 (Figure 4F).